C1P.F CONSUN PHARMAC.GR.HD -10

Healthcare Pharmaceuticals Frankfurt Exchange
1.77 EUR
Close of Nov 11, 2026
1.30 2.06
Market cap
EUR 1.48B
P/E
10.4x
P/B
2.35x
ROE
23.8%
Dividend yield
5.01%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is C1P.F undervalued?

Graham number
Price1.77
Graham value1.70
Premium4.2%

C1P.F trades 4.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CONSUN PHARMAC.GR.HD -10 fundamental analysis

No fundamental analysis for CONSUN PHARMAC.GR.HD -10 yet.

CONSUN PHARMAC.GR.HD -10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CONSUN PHARMAC.GR.HD -10

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well…

Full company profile